AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$1.96 USD
0.00 (-0.19%)
Updated Apr 26, 2024 01:33 PM ET
After-Market: $1.95 -0.01 (-0.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.96 USD
0.00 (-0.19%)
Updated Apr 26, 2024 01:33 PM ET
After-Market: $1.95 -0.01 (-0.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
by Zacks Equity Research
Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?
by Zacks Equity Research
Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.
Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
by Zacks Equity Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Lags Q4 Earnings Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -34.15% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Value Stocks to Buy for November 5th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 5th
Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Aeterna Zentaris (AEZS) a New Buy Stock
by Zacks Equity Research
Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aeterna Zentaris (AEZS) Beats Q2 Earnings Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 107.14% and -3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aeterna Zentaris (AEZS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Aeterna Zentaris (AEZS) Stock
by Zacks Equity Research
Aeterna Zentaris (AEZS) needs investors to pay close attention to the stock based on moves in the options market lately.